SCHEMBL3936688

SCHEMBL3936688

NC(=O)CC(=O)NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
STS P08842 2/20 0.43
GAA P10253 3/20 0.43
CES2 O00748 1/20 0.43
MAPT P10636 3/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
MMP1 P03956 2/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930045 0.82 TDP1 (0.45) ACP1TDP1STSGAACES2
SCHEMBL15880574 0.73 CA1 (0.68) ACP1TDP1STSGAACES2
SCHEMBL31027115 0.73 CYP1A2 (0.46) ACP1TDP1STSGAACES2
SCHEMBL13623382 0.73 CA1 (0.47) ACP1TDP1STSGAACES2
SCHEMBL3937372 0.71 SLC1A3 (0.43) ACP1TDP1STSGAACES2
SCHEMBL12054700 0.70 CA1 (0.44) ACP1TDP1STSGAACES2
SCHEMBL3458223 0.70 KIF11 (0.47) TDP1STSGAACES2MAPT
SCHEMBL13753684 0.69 MEN1 (0.50) GAAMAPTCA1CA2CA9
SCHEMBL2925179 0.69 STS (0.62) STSGAACES2CNR1
SCHEMBL15761593 0.68 PPARG (0.58) ACP1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258847-A1 Cholanic Acid Amides NOVARTIS AG (CH) 2009-10-15 US claimed
EP-2044100-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS Novartis AG (CH) 2009-04-08 EP claimed
WO-2008009407-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS NOVARTIS AG (CH) 2008-01-24 WO claimed
US-20090258847-A1 Cholanic Acid Amides NOVARTIS AG (CH) 2009-10-15 US disclosed
EP-2044100-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS Novartis AG (CH) 2009-04-08 EP disclosed
WO-2008009407-A2 SULPHONYLAMINOCARBONYL DERIVATIVES OF BILE ACID AMIDES FOR USE AS IMMUNOMODULATORS NOVARTIS AG (CH) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258847-A1 Cholanic Acid Amides NR1H4, SLC10A1, CYP46A1 ACP1 777/4885TDP1 2950/4885STS 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.